JP2017521457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521457A5 JP2017521457A5 JP2017503554A JP2017503554A JP2017521457A5 JP 2017521457 A5 JP2017521457 A5 JP 2017521457A5 JP 2017503554 A JP2017503554 A JP 2017503554A JP 2017503554 A JP2017503554 A JP 2017503554A JP 2017521457 A5 JP2017521457 A5 JP 2017521457A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocyclyl
- ome
- dioxanyl
- oxetanyl
- tetrahydrofuranyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- -1 [1,4] -dioxanyl Chemical group 0.000 claims 10
- 125000003566 oxetanyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 10
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical group CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462027376P | 2014-07-22 | 2014-07-22 | |
| US62/027,376 | 2014-07-22 | ||
| PCT/US2015/041245 WO2016014463A1 (en) | 2014-07-22 | 2015-07-21 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521457A JP2017521457A (ja) | 2017-08-03 |
| JP2017521457A5 true JP2017521457A5 (enExample) | 2018-08-30 |
| JP6602840B2 JP6602840B2 (ja) | 2019-11-06 |
Family
ID=53783363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017503554A Active JP6602840B2 (ja) | 2014-07-22 | 2015-07-21 | 可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9353090B2 (enExample) |
| EP (1) | EP3172202B1 (enExample) |
| JP (1) | JP6602840B2 (enExample) |
| KR (1) | KR20170035993A (enExample) |
| CN (1) | CN106459017B (enExample) |
| AP (1) | AP2016009615A0 (enExample) |
| AR (1) | AR101265A1 (enExample) |
| AU (1) | AU2015292833B2 (enExample) |
| BR (1) | BR112017000943A2 (enExample) |
| CA (1) | CA2955937A1 (enExample) |
| CL (1) | CL2017000071A1 (enExample) |
| CO (1) | CO2017000438A2 (enExample) |
| DK (1) | DK3172202T3 (enExample) |
| EA (1) | EA032972B1 (enExample) |
| ES (1) | ES2784477T3 (enExample) |
| HU (1) | HUE049231T2 (enExample) |
| IL (1) | IL249587A0 (enExample) |
| MX (1) | MX378717B (enExample) |
| PE (1) | PE20170249A1 (enExample) |
| PH (1) | PH12017500111A1 (enExample) |
| PL (1) | PL3172202T3 (enExample) |
| PT (1) | PT3172202T (enExample) |
| SG (2) | SG10201806565SA (enExample) |
| TW (1) | TWI711615B (enExample) |
| UY (1) | UY36226A (enExample) |
| WO (1) | WO2016014463A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108697678A (zh) * | 2016-02-01 | 2018-10-23 | 铁木医药有限公司 | sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用 |
| KR102608769B1 (ko) | 2016-09-14 | 2023-12-04 | 게노마티카 인코포레이티드 | 1,3-지방 디올 화합물 및 그 유도체 |
| CN109890379A (zh) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品 |
| CN106495999B (zh) * | 2016-10-18 | 2019-08-16 | 亳州学院 | 一种芳香醛及其合成方法 |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| TW201920197A (zh) | 2017-07-14 | 2019-06-01 | 英商葛蘭素史克智慧財產發展有限公司 | 化合物 |
| JP7461872B2 (ja) * | 2017-08-17 | 2024-04-04 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤における使用のための脂質 |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| US20210230155A1 (en) * | 2018-04-27 | 2021-07-29 | Hetero Labs Limited | Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one |
| WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| CA3100096A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| WO2020117493A1 (en) | 2018-12-03 | 2020-06-11 | Fmc Corporation | Method for preparing n-phenylpyrazole-1-carboxamides |
| CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| DK4182297T3 (da) | 2020-07-16 | 2025-12-01 | Acuitas Therapeutics Inc | Kationiske lipider til brug i lipid-nanopartikler |
| CN114957087A (zh) * | 2022-04-13 | 2022-08-30 | 湖南复瑞生物医药技术有限责任公司 | 一种帕罗韦德中间体制备方法 |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040067938A1 (en) | 2000-09-29 | 2004-04-08 | Penglie Zhang | Quaternary amines and related inhibitors of factor xa |
| MX2008000779A (es) | 2005-07-18 | 2008-02-21 | Bayer Healthcare Ag | Uso de activadores y estimuladores de guanilatociclasa solubles para la prevencion o tratamiento de trastornos renales. |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| RU2009145935A (ru) | 2007-05-12 | 2011-06-20 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| KR20100063109A (ko) | 2007-10-05 | 2010-06-10 | 사노피-아벤티스 도이칠란트 게엠베하 | 통증 치료에서 설포닐-치환된 2-설포닐아미노벤조산 ｎ-페닐아미드의 용도 |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| PE20091258A1 (es) | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
| US8461348B2 (en) | 2008-04-04 | 2013-06-11 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
| WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| WO2010015652A2 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
| WO2010065275A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EA201170942A1 (ru) | 2009-01-17 | 2012-02-28 | Байер Фарма Акциенгезельшафт | СТИМУЛЯТОРЫ рГЦ ИЛИ АКТИВАТОРЫ рГЦ В КОМБИНАЦИИ С ИНГИБИТОРАМИ ФДЭ5 ДЛЯ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ |
| EP2401265B1 (en) | 2009-02-26 | 2016-09-14 | Merck Sharp & Dohme Corp. | Derivatives of 1-pyri(mid)in-2-yl-pyrazole-4-carboxylic acid which are useful for therapy or prophylaxis of cardiovascular diseases |
| WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| AU2011212521B2 (en) | 2010-02-05 | 2015-11-19 | Adverio Pharma Gmbh | sGC stimulators or sGC activators alone and in combination with PDE5 inhbitors for the treatment of Cystic Fibrosis |
| AU2011257336B2 (en) | 2010-05-26 | 2015-11-19 | Adverio Pharma Gmbh | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc). |
| US20130158028A1 (en) | 2010-06-25 | 2013-06-20 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP5715713B2 (ja) * | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| WO2013025425A1 (en) * | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| SG10201510668UA (en) | 2012-09-07 | 2016-01-28 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| WO2015095515A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
-
2015
- 2015-07-21 AP AP2016009615A patent/AP2016009615A0/en unknown
- 2015-07-21 CA CA2955937A patent/CA2955937A1/en not_active Abandoned
- 2015-07-21 TW TW104123596A patent/TWI711615B/zh not_active IP Right Cessation
- 2015-07-21 US US14/804,363 patent/US9353090B2/en active Active
- 2015-07-21 DK DK15747311.7T patent/DK3172202T3/da active
- 2015-07-21 PT PT157473117T patent/PT3172202T/pt unknown
- 2015-07-21 BR BR112017000943A patent/BR112017000943A2/pt not_active Application Discontinuation
- 2015-07-21 AR ARP150102304A patent/AR101265A1/es unknown
- 2015-07-21 ES ES15747311T patent/ES2784477T3/es active Active
- 2015-07-21 WO PCT/US2015/041245 patent/WO2016014463A1/en not_active Ceased
- 2015-07-21 EA EA201790246A patent/EA032972B1/ru not_active IP Right Cessation
- 2015-07-21 SG SG10201806565SA patent/SG10201806565SA/en unknown
- 2015-07-21 AU AU2015292833A patent/AU2015292833B2/en not_active Ceased
- 2015-07-21 SG SG11201700507XA patent/SG11201700507XA/en unknown
- 2015-07-21 MX MX2017000926A patent/MX378717B/es unknown
- 2015-07-21 PE PE2017000087A patent/PE20170249A1/es unknown
- 2015-07-21 CN CN201580033515.4A patent/CN106459017B/zh active Active
- 2015-07-21 PL PL15747311T patent/PL3172202T3/pl unknown
- 2015-07-21 HU HUE15747311A patent/HUE049231T2/hu unknown
- 2015-07-21 KR KR1020177004761A patent/KR20170035993A/ko not_active Withdrawn
- 2015-07-21 JP JP2017503554A patent/JP6602840B2/ja active Active
- 2015-07-21 EP EP15747311.7A patent/EP3172202B1/en active Active
- 2015-07-22 UY UY0001036226A patent/UY36226A/es unknown
-
2016
- 2016-12-15 IL IL249587A patent/IL249587A0/en unknown
-
2017
- 2017-01-11 CL CL2017000071A patent/CL2017000071A1/es unknown
- 2017-01-18 PH PH12017500111A patent/PH12017500111A1/en unknown
- 2017-01-19 CO CONC2017/0000438A patent/CO2017000438A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521457A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| HRP20191755T1 (hr) | Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze | |
| JP2013510124A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2015518491A5 (enExample) | ||
| JP2010522184A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| CU20160189A7 (es) | Ácidos grasos útiles en la conjugación con biomoléculas | |
| JP2017533968A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2014533259A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2017520613A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2016515560A5 (enExample) | ||
| JP2017534662A5 (enExample) | ||
| JP2015523406A5 (enExample) | ||
| JP2017534663A5 (enExample) | ||
| JP2017517512A5 (enExample) | ||
| JP2016528273A5 (enExample) |